ALPS Advisors’s Adverum Biotechnologies ADVM Stock Holding History

ALPS Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,027	Closed	-$261K	–	891
2021 Q3	$261K	Sell	12,027 -872	-7%	-$22.3K	﹤0.01%	880
2021 Q2	$451K	Buy	+12,899	New	+$695K	﹤0.01%	534

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

ALPS Advisors's ADVM Position: Q4 2021 in Review

ALPS Advisors sold out of Adverum Biotechnologies (ADVM) in Q4 2021, closing a stake of 12,027 shares — an estimated $261K sold.

ALPS Advisors first reported a position in ADVM in Q2 2021 and held it in 2 quarters. The position peaked at $451K in Q2 2021. 98 funds tracked by Wall St. Rank hold ADVM as of Q4 2021.

ALPS Advisors reported no remaining Adverum Biotechnologies position as of Q4 2021 after selling out during the quarter.
ALPS Advisors sold 12,027 Adverum Biotechnologies shares in Q4 2021, an estimated $261K.
ALPS Advisors first reported a position in Adverum Biotechnologies in Q2 2021 and held it in 2 quarters.
ALPS Advisors's Adverum Biotechnologies position peaked at $451K in Q2 2021.
98 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2021.

Based on ALPS Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.